Trust Signals
Written by the FormBlends Medical Team. Every claim is labeled with its evidence tier. Speculative mechanisms are marked as such. No products are sold on this page. Updated 2026-05-29.
Key Takeaways
- The only peptides with robust human RCT fat-loss data are FDA-approved GLP-1 receptor agonists, semaglutide produced roughly 14.9% body weight reduction in the STEP 1 trial (n=1961, 68 weeks).
- Tesamorelin, an FDA-approved GHRH analogue, reduced visceral adipose tissue by roughly 15 to 18% in HIV-lipodystrophy trials. That approval does not extend to healthy adults seeking general fat loss.
- The CJC-1295 plus ipamorelin combination is mechanistically rational but has no published human RCT demonstrating fat loss as a primary endpoint.
- AOD-9604 failed a Phase IIb human RCT for weight loss; its developer discontinued the obesity indication. Animal data did not translate.
- Purity and endotoxin contamination are the largest real-world risks of research-grade peptides, not the peptide mechanism itself.
What Is the Best Peptide Stack for Fat Loss?
If evidence strength is the criterion, the best peptide stack for fat loss is an FDA-approved GLP-1 agonist used under physician supervision, not a research compound combination. Among research-compound stacks, a GHRH analogue paired with a selective GHRP (such as CJC-1295 with ipamorelin) has the most mechanistic rationale, but human fat-loss trial data for that exact stack does not exist. Honest answer: the gap between marketing and evidence is large.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Evidence Ledger: Each Major Peptide Rated
- How Fat-Loss Peptides Work: Mechanisms with Numbers
- The Main Stacks, Ranked by Evidence
- What Most Pages Get Wrong About Peptide Stacks
- Why the Storage and Stability Rules Exist
- Honest Head-to-Head: Peptide Stacks vs Approved Alternatives
- Label and COA Literacy: How to Judge a Product Yourself
- Dosing Reference Table
- FAQ
- Sources
- Footer Disclaimers
Evidence Ledger: Each Major Peptide Rated
Each row reflects the best available evidence specifically for fat loss or body composition as a measured endpoint. Evidence for other indications (wound healing, GH deficiency treatment) is not counted here.
| Peptide | Best Evidence Type | Effect on Fat Mass | Confidence (Fat Loss) | Key Caveat |
|---|---|---|---|---|
| Semaglutide (GLP-1 RA) | Human RCT, n=1961, 68 weeks (STEP 1) | Approx. 14.9% body weight reduction | High | FDA-approved; not a research compound. Nausea, GI side effects common. |
| Tirzepatide (GLP-1/GIP dual RA) | Human RCT, SURMOUNT-1 trial | Up to approx. 20.9% body weight reduction at highest dose | High | FDA-approved for obesity. Dual agonist; different side-effect profile than semaglutide alone. |
| Tesamorelin | Human RCT in HIV lipodystrophy | Approx. 15 to 18% VAT reduction in approved population | Moderate (specific population) | Off-label for healthy adults. Visceral fat only, not total body fat. |
| CJC-1295 (with DAC) | Small human pharmacokinetic studies; no fat-loss RCT | GH and IGF-1 elevation documented; fat loss not a primary endpoint | Low | Half-life extended to approx. 6 to 8 days with DAC. Fat loss extrapolated from GH physiology, not direct trial data. |
| Ipamorelin | Animal studies, small human GH-pulse studies | GH secretion increase; no human fat-loss RCT | Low | Selective GHRP with low cortisol and prolactin elevation. Fat loss is inferred, not demonstrated. |
| AOD-9604 (hGH fragment 177-191) | Phase IIb human RCT (Metabolic Pharmaceuticals) | No significant difference vs placebo for weight loss in humans | Low (failed endpoint) | Animal lipolysis data did not translate. Program discontinued for obesity. |
| BPC-157 | Animal studies, no human RCT for fat loss | No established fat loss mechanism or data | Very Low | Included in stacks for recovery rationale, not adiposity reduction. |
| MOTS-c | Animal studies; early human metabolic data | Improved insulin sensitivity and reduced adiposity in mice | Very Low | Mitochondrial-derived peptide. Human fat-loss data is preliminary and limited. |
How Fat-Loss Peptides Work: Mechanisms with Numbers
GLP-1 Receptor Agonists
Glucagon-like peptide-1 (GLP-1) is a 30-amino acid incretin hormone released from intestinal L-cells. It slows gastric emptying, suppresses glucagon, and acts on hypothalamic GLP-1 receptors to reduce appetite. Semaglutide, a GLP-1 analogue with a fatty acid chain enabling albumin binding, has a half-life of approximately 1 week, enabling once-weekly dosing. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) demonstrated that 2.4 mg weekly subcutaneous semaglutide reduced mean body weight by 14.9% versus 2.4% for placebo over 68 weeks. That difference is large by any clinical standard.
What this mechanism does NOT prove: that GLP-1 agonists are "peptide stacks" in the research-compound sense, or that the fat loss is maintained after discontinuation without behavioral change.
GHRH Analogues and GHRPs
Growth hormone-releasing hormone (GHRH) binds pituitary GHRH receptors, triggering GH pulsatile release. CJC-1295 is a synthetic GHRH analogue. The version with Drug Affinity Complex (DAC) covalently binds to circulating albumin, extending its half-life to roughly 6 to 8 days per a 2006 pharmacokinetic study by Jetté et al. published in Growth Hormone and IGF Research. GH itself promotes lipolysis via hormone-sensitive lipase activation and suppression of lipoprotein lipase, particularly in visceral adipose tissue. In GH-deficient adults, GH replacement reduces fat mass meaningfully. In GH-sufficient healthy adults, the incremental fat-loss effect of further GH elevation is substantially smaller.
Ipamorelin is a pentapeptide GHRP that binds the ghrelin receptor (GHSR-1a) with relative selectivity, producing GH pulses with less cortisol and prolactin elevation than earlier GHRPs like GHRP-6. That selectivity is a real pharmacological advantage but does not translate into proven fat loss in a human RCT.
GHRH and GHRP Synergy
Combining a GHRH analogue with a GHRP creates supra-additive GH release, because GHRH and ghrelin receptor agonists act on different intracellular pathways (cAMP versus phospholipase C) that converge at the somatotroph. This synergy is well documented in pituitary physiology and is the mechanistic rationale for CJC-1295 plus ipamorelin stacking. The caveat: documented GH elevation is not the same as documented fat loss, particularly in a caloric surplus or maintenance state.
The Main Stacks, Ranked by Evidence
Stack 1: Semaglutide or Tirzepatide (Approved, Prescribed)
These are peptides. They are also the only peptides with large-scale human RCT data for fat loss. If fat loss is the primary goal, these belong at the top of any evidence-ranked list. They require a prescription, physician oversight, and come from regulated pharmacies.
Stack 2: Tesamorelin (Approved, Narrow Indication)
For visceral adipose tissue specifically in the approved HIV-lipodystrophy population, tesamorelin has genuine human evidence. Off-label, its use is not supported by the same data strength.
Stack 3: CJC-1295 with DAC plus Ipamorelin (Research Compound)
This is the most pharmacologically coherent research-compound stack for GH-driven lipolysis. Typical community-reported protocols involve 100 to 300 mcg ipamorelin combined with 1 to 2 mg CJC-1295 with DAC, dosed 1 to 2 times per week. There is no published human fat-loss RCT for this combination. Effect in GH-sufficient adults seeking fat loss is likely modest and highly dependent on caloric deficit and training status.
Stack 4: Sermorelin plus Ipamorelin (Research Compound)
Sermorelin is a truncated GHRH analogue (residues 1 to 29 of endogenous GHRH). It has a shorter half-life than CJC-1295, requiring more frequent dosing, but is used in compounded formulations. Evidence tier is the same as the CJC-1295 stack: mechanistically rationale, human fat-loss RCT absent.
Stack 5: AOD-9604 (Research Compound, Failed Endpoint)
Despite heavy promotion, AOD-9604 failed its primary weight-loss endpoint in a Phase IIb human study. It should not appear in evidence-based rankings. Animal data was not predictive.
What Most Pages Get Wrong About Peptide Stacks
This is the section competitors omit.
Animal-to-human translation failure is common. AOD-9604 is the clearest example. Rodents have fundamentally different GH pulsatility and adipose tissue responses. Positive animal lipolysis data generated commercial excitement. The human RCT was negative. This pattern repeats across many peptide candidates.
GH elevation is not the same as fat loss. CJC-1295 studies documented elevated GH and IGF-1 levels. Most peptide blog posts stop there and assert fat loss follows. GH-driven lipolysis is real physiology, but its magnitude in GH-sufficient adults with modest pharmacological GH elevation, in the absence of a verified caloric deficit, is not established by trial data.
The purity problem is larger than the mechanism problem. A 2018 analysis published in the Journal of the American Medical Association found that among compounded peptides, impurities and mislabeling are common outside of regulated pharmacies. Research-grade peptides sold through non-pharmacy online vendors are not manufactured under FDA cGMP. Endotoxin contamination from gram-negative bacterial cell walls (lipopolysaccharide) in injectable products causes fever, inflammation, and in severe cases septic shock. A peptide with a solid mechanism but 5 EU per mL of endotoxin is not safe.
Stack synergy is marketing language without dosing data. Saying two peptides synergize is not the same as knowing the optimal dose ratio, timing, or whether the combination changes the safety profile. No published study has optimized a CJC-1295 plus ipamorelin fat-loss protocol in humans.
Why the Storage and Stability Rules Exist
Lyophilized (freeze-dried) peptides are kinetically stable at low temperatures because removing water eliminates the primary hydrolysis reaction. Peptide bonds are hydrolyzed by water in a reaction that is accelerated by heat and by extremes of pH. A lyophilized vial stored at 2 to 8 degrees Celsius is protected because both available water and thermal energy are minimized.
Once reconstituted with bacteriostatic water (water containing 0.9% benzyl alcohol as a preservative), two degradation pathways become active. First, hydrolysis of peptide bonds, particularly at asparagine-glycine sequences, proceeds over days to weeks at refrigerator temperature. Second, oxidation of methionine and tryptophan residues occurs when the solution is exposed to light or oxygen. This is why reconstituted peptide solutions should be kept in the dark and used within approximately 28 days.
Why bacteriostatic water and not sterile water: plain sterile water for injection is not preserved. A multi-dose vial reconstituted with plain sterile water supports bacterial growth within hours at room temperature, and even at refrigerator temperature, microbial proliferation is not fully arrested. Benzyl alcohol at 0.9% provides bacteriostatic (growth-inhibiting) activity. Note: benzyl alcohol is contraindicated in neonates due to gasping syndrome, but this is not a relevant population for fat-loss peptide protocols.
Repeated freeze-thaw cycles of reconstituted peptide solutions accelerate denaturation and aggregation. The mechanical stress of ice crystal formation disrupts peptide tertiary structure. If you cannot use a vial within 28 days, the correct approach is to aliquot and freeze the reconstituted solution once and avoid further freeze-thaw cycles, though this is not ideal and is generally not necessary if vials are sized appropriately.
Honest Head-to-Head: Peptide Stacks vs Approved Alternatives
| Criterion | CJC-1295 plus Ipamorelin (Research Stack) | Semaglutide 2.4 mg/week (Approved) | Orlistat 120 mg TID (Approved Small Molecule) |
|---|---|---|---|
| Human fat-loss RCT data | None as primary endpoint | Yes, n=1961, 68 weeks (STEP 1) | Yes, multiple trials; approx. 3 kg additional vs placebo at 1 year |
| Mean fat/weight reduction (trial data) | Not quantified | Approx. 14.9% body weight | Approx. 2.9 to 3.4 kg vs placebo (smaller effect) |
| Regulatory status | Research compound, not FDA-approved for this use | FDA-approved (Wegovy) | FDA-approved (Xenical, Alli) |
| Route | Subcutaneous injection | Subcutaneous injection | Oral |
| Primary side effects | Injection site reactions, water retention, potential glucose dysregulation; unknown long-term | Nausea (common), vomiting, pancreatitis risk, possible thyroid C-cell effects (rodent data) | Fecal fat leakage, GI urgency, fat-soluble vitamin malabsorption |
| Purity assurance | Depends on vendor; no cGMP requirement for research compounds | cGMP manufacturing, pharmacovigilance program | cGMP manufacturing |
| Where research stack wins | Potentially lower cost in some markets; may support lean mass alongside fat loss via GH mechanism; no GI side effects typical of GLP-1 agonists | N/A | N/A |
| Where research stack loses | No proven human fat-loss data, no purity guarantee, no pharmacovigilance, unknown long-term safety | N/A | N/A |
Label and COA Literacy: How to Judge a Product Yourself
If you are evaluating a research peptide product, here is what to look for and why each item matters.
HPLC Purity. High-performance liquid chromatography separates peptide from impurities by retention time. A purity reading above 98% by HPLC is a reasonable standard. Below 95% means a meaningful fraction of the injected material is something other than the labeled peptide. Always ask which column and gradient were used; a poorly chosen method can show artificially high purity.
Mass Spectrometry (MS) Confirmation. HPLC purity tells you how much of the main peak is present. MS tells you whether that main peak is actually the correct peptide. Request a mass spectrum that matches the expected molecular weight of the peptide to within 1 to 2 daltons. For example, ipamorelin has a molecular weight of approximately 711.9 g/mol. If the COA shows a different mass, the peptide is wrong.
Endotoxin Testing. The USP standard for injectable products is less than 5 EU per kg body weight per hour. For a 100 mcg peptide injection, the practical standard many compounding pharmacies apply is below 1 EU per mL. Endotoxin testing is done by limulus amebocyte lysate (LAL) assay or the newer recombinant Factor C method. A COA without endotoxin testing for an injectable product is incomplete.
Sterility Testing. USP 71 sterility test requires 14-day incubation with positive and negative controls. This is rarely performed by research vendors. At a minimum, bacteriostatic water should be used for reconstitution of any multi-dose product.
Third-Party vs In-House COA. A COA produced by the same company selling the product has an obvious conflict of interest. Request COAs from independent accredited labs. The lab name and accreditation number should appear on the document.
What degradation looks like. A compromised lyophilized peptide vial may show visible particulate matter, discoloration (yellowing or browning suggests oxidation), or clumping. A degraded reconstituted solution may appear cloudy or have visible precipitate. These are signals to discard the product. You cannot confirm potency by appearance alone, but visible degradation is a hard stop.
Dosing Reference Table (Research Compound Context)
| Peptide | Reported Dose Range | Frequency (Community Reports) | Route | Evidence Basis for Dose |
|---|---|---|---|---|
| CJC-1295 with DAC | 1 to 2 mg | Once or twice weekly | Subcutaneous | Jetté et al. 2006 pharmacokinetic study; half-life approx. 6 to 8 days |
| Ipamorelin | 100 to 300 mcg | Once or twice daily | Subcutaneous | Animal and small human GH-pulse studies; half-life approximately 2 hours |
| Sermorelin | 200 to 500 mcg | Daily or 5 days on, 2 off | Subcutaneous | Historical GHRH research; compounding pharmacy protocols |
| Tesamorelin (approved use) | 2 mg | Daily | Subcutaneous | FDA-approved prescribing information (Egrifta) |
| Semaglutide (approved use) | 0.25 mg titrated to 2.4 mg | Weekly | Subcutaneous | STEP 1 trial; FDA-approved prescribing information (Wegovy) |
FAQ
Sources
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2021;384(11):989-1002. (STEP 1 trial)
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022;387(3):205-216. (SURMOUNT-1 trial)
- Falutz J, et al. "Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV." New England Journal of Medicine. 2007;357(23):2359-2370. (Tesamorelin in HIV lipodystrophy)
- Jetté L, et al. "Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats." Journal of Endocrinology. 2005;184(1):105-116.
- Alba M, et al. "Once-monthly administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse." American Journal of Physiology Endocrinology and Metabolism. 2006;291(6):E1290-E1294.
- Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology. 1998;139(5):552-561.
- Metabolic Pharmaceuticals. AOD-9604
Related peptide guides